Eli Lilly ( LLY +0.87%) delivered a gain worthy of a technology growth stock last year. The pharma giant's shares soared 39%, ...

The choice isn't that hard.

By Bhanvi Satija and Maggie Fick LONDON, Jan 16 (Reuters) - Novo Nordisk's Wegovy weight-loss pill has made an "encouraging" ...

By Sabrina Valle NEW YORK, Jan 20 (Reuters) - Abivax Chief Executive Marc de Garidel dismissed as "noise" reports in the ...

We look at the Novo Nordisk A/S outlook for 2026: new CEO focus, oral Wegovy edge vs Eli Lilly, and double-digit growth ...

By Sriparna Roy Jan 23 (Reuters) - Novo Nordisk's Wegovy pill was prescribed more than 18,000 times in the U.S. in the first ...

Novo Nordisk's Wegovy pill was prescribed 18,410 times in the U.S. in the first full week after its launch in an encouraging ...

With just a few months to go before Eli Lilly expects to launch its own oral GLP-1 obesity drug, Novo Nordisk is making the ...

Eli Lilly (LLY) downgraded to Sell as obesity-drug competition and pricing pressure rise; stretched valuation boosts downside ...

Novo Nordisk oral Wegovy records 3,071 prescriptions in four days. Shares jump 6.5% as Eli Lilly oral weight loss drug awaits ...

Strive Specialities Inc., a major provider of compounded medicines, filed a federal lawsuit against pharmaceutical giants Eli ...

Eli Lilly is Wednesday's IBD Stock Of The Day. Lilly shares are bounding off their 50-day line with a new buying opportunity ...